191 related articles for article (PubMed ID: 18711705)
1. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
Patterson MK; Castellsague J; Walker AM
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):982-8. PubMed ID: 18711705
[TBL] [Abstract][Full Text] [Related]
2. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
[TBL] [Abstract][Full Text] [Related]
3. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
Goldstein JL; Silverstein FE; Agrawal NM; Hubbard RC; Kaiser J; Maurath CJ; Verburg KM; Geis GS
Am J Gastroenterol; 2000 Jul; 95(7):1681-90. PubMed ID: 10925968
[TBL] [Abstract][Full Text] [Related]
4. Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States.
Goldstein JL; Zhao SZ; Burke TA; Palmer R; von Allmen H; Henderson SC
Am J Gastroenterol; 2003 Dec; 98(12):2627-34. PubMed ID: 14687808
[TBL] [Abstract][Full Text] [Related]
5. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790
[TBL] [Abstract][Full Text] [Related]
6. Underutilization of preventive strategies in patients receiving NSAIDs.
Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
[TBL] [Abstract][Full Text] [Related]
7. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
[TBL] [Abstract][Full Text] [Related]
8. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
[TBL] [Abstract][Full Text] [Related]
9. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. A large health maintenance organization cohort study.
Lanza LL; Walker AM; Bortnichak EA; Dreyer NA
Arch Intern Med; 1995 Jul; 155(13):1371-7. PubMed ID: 7794085
[TBL] [Abstract][Full Text] [Related]
10. Adverse Drug Events Involving COX-2 Inhibitors.
Verrico MM; Weber RJ; McKaveney TP; Ansani NT; Towers AL
Ann Pharmacother; 2003 Sep; 37(9):1203-13. PubMed ID: 12921500
[TBL] [Abstract][Full Text] [Related]
11. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease.
Shorr RI; Ray WA; Daugherty JR; Griffin MR
Arch Intern Med; 1993 Jul; 153(14):1665-70. PubMed ID: 8333804
[TBL] [Abstract][Full Text] [Related]
12. Persistence with COX-2 inhibitors in managed care: an analysis of claims data.
Harley C; Wagner S
Manag Care Interface; 2003 Oct; 16(10):38-45. PubMed ID: 14606259
[TBL] [Abstract][Full Text] [Related]
13. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
Wolfe F; Michaud K; Burke TA; Zhao SZ
J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
[TBL] [Abstract][Full Text] [Related]
14. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec.
Moride Y; Ducruet T; Rochon S; Lavoie F
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii17-22. PubMed ID: 14585914
[TBL] [Abstract][Full Text] [Related]
15. Selective COX-2 inhibitors and gastrointestinal mucosal injury: pharmacological and therapeutic considerations.
Dajani EZ; Agrawal NM
J Assoc Acad Minor Phys; 2000; 11(2-3):28-31. PubMed ID: 10953541
[TBL] [Abstract][Full Text] [Related]
16. Risk factors associated with the development of gastroduodenal ulcers due to the use of NSAIDs.
Wolfe MM
Int J Clin Pract Suppl; 2003 Apr; (135):32-7. PubMed ID: 12723745
[TBL] [Abstract][Full Text] [Related]
17. Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases.
McGettigan P; Han P; Jones L; Whitaker D; Henry D
Br J Clin Pharmacol; 2008 Jun; 65(6):927-34. PubMed ID: 18384446
[TBL] [Abstract][Full Text] [Related]
18. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.
Mamdani M; Rochon P; Juurlink DN; Anderson GM; Kopp A; Naglie G; Austin PC; Laupacis A
Arch Intern Med; 2003 Feb; 163(4):481-6. PubMed ID: 12588209
[TBL] [Abstract][Full Text] [Related]
19. Peptic ulcer disease and the nonsteroidal anti-inflammatory drugs.
Peoples JB
Am Surg; 1985 Jun; 51(6):358-62. PubMed ID: 3994179
[TBL] [Abstract][Full Text] [Related]
20. The epidemiology of NSAID associated gastrointestinal disease.
Wolfe F
Eur J Rheumatol Inflamm; 1991; 11(3):12-28. PubMed ID: 1365476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
